Factors influencing uptake of pharmacogenetic testing in a diverse patient population

J. O'daniel, J. Lucas, P. Deverka, D. Ermentrout, G. Silvey, D. F. Lobach, S. B. Haga

Research output: Contribution to journalArticle

Abstract

Background: The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history. Methods: We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center. Results: Of 75 completed surveys (65% African-American), 77% indicated they were 'very likely' or 'somewhat likely' to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing. Conclusions: We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalPublic Health Genomics
Volume13
Issue number1
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Insurance Coverage
Privacy
Social Class
Population
Insurance
African Americans
Medicine
Learning
Safety
Pharmaceutical Preparations
Pharmacogenomic Testing
Surveys and Questionnaires

Keywords

  • Pharmacogenetic testing
  • Public attitudes
  • Side effects

ASJC Scopus subject areas

  • Genetics(clinical)
  • Public Health, Environmental and Occupational Health

Cite this

O'daniel, J., Lucas, J., Deverka, P., Ermentrout, D., Silvey, G., Lobach, D. F., & Haga, S. B. (2009). Factors influencing uptake of pharmacogenetic testing in a diverse patient population. Public Health Genomics, 13(1), 48-54. https://doi.org/10.1159/000217795

Factors influencing uptake of pharmacogenetic testing in a diverse patient population. / O'daniel, J.; Lucas, J.; Deverka, P.; Ermentrout, D.; Silvey, G.; Lobach, D. F.; Haga, S. B.

In: Public Health Genomics, Vol. 13, No. 1, 01.09.2009, p. 48-54.

Research output: Contribution to journalArticle

O'daniel, J, Lucas, J, Deverka, P, Ermentrout, D, Silvey, G, Lobach, DF & Haga, SB 2009, 'Factors influencing uptake of pharmacogenetic testing in a diverse patient population', Public Health Genomics, vol. 13, no. 1, pp. 48-54. https://doi.org/10.1159/000217795
O'daniel J, Lucas J, Deverka P, Ermentrout D, Silvey G, Lobach DF et al. Factors influencing uptake of pharmacogenetic testing in a diverse patient population. Public Health Genomics. 2009 Sep 1;13(1):48-54. https://doi.org/10.1159/000217795
O'daniel, J. ; Lucas, J. ; Deverka, P. ; Ermentrout, D. ; Silvey, G. ; Lobach, D. F. ; Haga, S. B. / Factors influencing uptake of pharmacogenetic testing in a diverse patient population. In: Public Health Genomics. 2009 ; Vol. 13, No. 1. pp. 48-54.
@article{cda92f84ad2647e1a6c471d9f6b04f5d,
title = "Factors influencing uptake of pharmacogenetic testing in a diverse patient population",
abstract = "Background: The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history. Methods: We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center. Results: Of 75 completed surveys (65{\%} African-American), 77{\%} indicated they were 'very likely' or 'somewhat likely' to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing. Conclusions: We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.",
keywords = "Pharmacogenetic testing, Public attitudes, Side effects",
author = "J. O'daniel and J. Lucas and P. Deverka and D. Ermentrout and G. Silvey and Lobach, {D. F.} and Haga, {S. B.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1159/000217795",
language = "English (US)",
volume = "13",
pages = "48--54",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Factors influencing uptake of pharmacogenetic testing in a diverse patient population

AU - O'daniel, J.

AU - Lucas, J.

AU - Deverka, P.

AU - Ermentrout, D.

AU - Silvey, G.

AU - Lobach, D. F.

AU - Haga, S. B.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Background: The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history. Methods: We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center. Results: Of 75 completed surveys (65% African-American), 77% indicated they were 'very likely' or 'somewhat likely' to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing. Conclusions: We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.

AB - Background: The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history. Methods: We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center. Results: Of 75 completed surveys (65% African-American), 77% indicated they were 'very likely' or 'somewhat likely' to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing. Conclusions: We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.

KW - Pharmacogenetic testing

KW - Public attitudes

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=77951130342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951130342&partnerID=8YFLogxK

U2 - 10.1159/000217795

DO - 10.1159/000217795

M3 - Article

C2 - 19407441

AN - SCOPUS:77951130342

VL - 13

SP - 48

EP - 54

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 1

ER -